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Thyrotoxicosis affects 1-3.5% of all pregnancies and its
major cause is gestational hyperthyroidism and Graves’
disease, less common – multinodular toxic goiter and
toxic adenoma, and rare – subacute or silent thyroiditis
and struma ovarii.
Gestational hyperthyroidism is a transient form of thyro-
toxicosis caused by excessive stimulation of thyroid gland
by hCG and usually limited to the first 12-16 weeks of
pregnancy. It affects 1-3% of all pregnancies, especially the
women with hyperemesis gravidarum and multiple gesta-
tion. It can also occur in hydatidiform mole and choriocar-
cinoma. The rare cause of gestational hyperthyroidism is a
functional mutation of TSH receptor which results in
hypersensitivity of thyroid gland to hCG.
Graves’ disease is recognized in 0.1-0.4% of all preg-
nancies. The symptoms of hyperthyroidism usually
exacerbate in the first trimester, diminish in the second
one and completely subside in the third in 20-30% of
affected women. Graves’ disease can be differentiated
from gestational thyrotoxicosis by the clinical and
laboratory presence of autoimmunity: orbitopathy, typi-
cal goiter and TSH receptor antibodies (TRAb).
Multinodular toxic goiter and toxic adenoma are the
very rare cases of hyperthyroidism in pregnancy because
these conditions typically occur in the older population.
Overt hyperthyroidism constitutes a special risk to
mother and fetus. It can precipitate hypertension, conges-
tive heart failure and preeclampsia in pregnant woman.
The higher rate of miscarriage, preterm delivery and pla-
cental abruption are also noted. In Graves’ disease trans-
placental passage of TRAb can induce fetal and neonatal
hyperthyroidism. The fetal effects can be seen after 20
weeks’ gestation and include tachycardia, cardiomegaly,
hydrops, advanced bone age, intrauterine growth restric-
tion and stillbirths. Suppression of the fetal TSH can be
the cause of central hypothyroidism later on. Antithyroid
drugs (ATDs) also freely cross the placenta and can cause
fetal hypothyroidism with bradycardia, growth retardation
and delayed bone maturation.
Overt hyperthyroidism due to Graves’ disease, multinod-
ular goiter or toxic adenoma should be treated with ATDs.
The aim of ATD therapy is to maintain free HT in the
upper limit of the normal reference range or slightly
above. The recommended medication in the first trimester
is propylthiouracil (PTU) because its use is not associated
with congenital abnormalities. Alternatively methimazole
(MMI) can be instituted in the case of PTU allergy. In the
second and third trimester the use of MMI is preferred
because of the possible PTU hepatotoxicity. Serum TSH,
and free TH should be monitored every 2-6 weeks. Sur-
gery is indicated in second trimester in the case of severe
adverse reactions to ATDs, when high doses of ATDs are
persistently needful or when patient is not compliant with
ATD therapy. Radioiodine therapy is forbidden in preg-
nancy because of deleterious effect of radiation on the
fetus and possibility of ablation of fetal thyroid when used
after 12 weeks’ gestation.
Fetal ultrasound monitoring is recommended in preg-
nant women with elevated TRAb or treated with ATD
from 18-22 or 20-24 weeks’ gestation. The aim is to diag-
nose fetal thyroid dysfunction. Cordocentesis in an
attempt to determine fetal TSH and TH is warranted only
in selected cases when clinical data are confounding.
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